Abeona Therapeutics (ABEO) vs Prelude Therapeutics (PRLD)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
Prelude Therapeutics (PRLD) has outperformed Abeona Therapeutics (ABEO) over the past year, gaining 166.0% versus a loss of 3.2%. Over five years, PRLD leads with a -76.4% price change compared with -77.7% for ABEO. Prelude Therapeutics is the larger company by market cap ($309.6 million vs $283.6 million), about 1.1 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | ABEO | PRLD |
|---|---|---|
| Share price | $4.96 | $3.88 |
| Market cap | $283.63M | $309.64M |
| 1-day change | -2.36% | +1.31% |
| YTD return | -3.61% | +32.07% |
| 1-year return | -3.24% | +165.97% |
| 5-year return | -77.67% | -76.45% |
| EPS (TTM) | $-1.18 | $-0.73 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $7.65 | $6.83 |
| 52-week low | $4.00 | $1.15 |
| Distance from 52-week high | -35.16% | -43.19% |
| Analyst consensus | strong_buy | strong_buy |
| Avg. price target upside | +280.65% | +137.11% |
| Average volume | 1.41M | 477.45K |
| Shares outstanding | 57.18M | 65.08M |
| Employees | 226 | 79 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- PRLD has outperformed ABEO by 169.2 percentage points over the past year.
About Abeona Therapeutics
ABEO stock →Abeona Therapeutics Inc., a commercial-stage biopharmaceutical company, develops gene and cell therapies for life-threatening diseases in the United States. It develops ZEVASKYN, an autologous, cell-based gene therapy for the treatment of patients with recessive dystrophic epidermolysis bullosa.
Health Care · Biotechnology: Pharmaceutical Preparations · 226 employees
About Prelude Therapeutics
PRLD stock →Prelude Therapeutics Incorporated, a clinical-stage precision oncology company, focuses on the discovery and development of novel precision cancer medicines to underserved patients. It is developing JAK2V617F, a driver mutation product for the treatment of myeloproliferative neoplasms, myelofibrosis (MF), polycythemia vera, and essential thrombocythemia (ET); KAT6A for the treatment of advanced breast cancer and other solid tumors; and mutated calreticulin degrader antibody conjugates to treat MF and ET.
Health Care · Biotechnology: Pharmaceutical Preparations · 79 employees
ABEO vs PRLD FAQ
Which is bigger, Abeona Therapeutics or Prelude Therapeutics?
Prelude Therapeutics (PRLD) is larger, with a market capitalization of $309.64M compared with $283.63M for Abeona Therapeutics (ABEO).
Which stock has performed better over the past year, ABEO or PRLD?
PRLD returned +165.97% over the past 12 months, compared with -3.24% for ABEO (price return, excluding dividends). Past performance does not predict future results.
Are Abeona Therapeutics and Prelude Therapeutics in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.